Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 3

Effects of Emab on IL-6 and IL-10 cytokine production. Tonsillar CD10–CD27– B cells were negatively selected using magnetic bead cell enrichment and then stimulated with R848 and/or F(ab′)2 anti-human IgM with or without Emab or a human IgG control. a, b Cells were treated with different stimuli and cultured for 3 days, and production of IL-6 and IL-10 in cell supernatants was quantified by ELISA. Cumulative data from nine independent experiments using CD10–CD27– B cells from different donors. Experiments with increased IL-6 production in the presence of Emab are shown (gray) (a). c Correlation between TLR7 mRNA expression in donor CD10–CD27– B cells at the time of activation and the levels of IL-10 produced 3 days after anti-IgM/R848 stimulation. **p < 0.01 by two-way ANOVA analysis with Bonferroni post tests. Emab epratuzumab, IL interleukin, TLR7 Toll-like receptor 7

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us